The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: A multi-center randomized trial.
Urol. Oncol., Dec (2011)
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
J. Clin. Oncol., Jun;28(16):2668-73 (2010)
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
Cancer., May;112(10):2181-7 (2008)
Factors that predict treatment choice and satisfaction with the decision in men with localized prostate cancer.
Clin Genitourin Cancer., Dec;5(3):219-26 (2006)
Actual use and perceived usefulness of a web-based, decision support program for men with prostate cancer.
Stud Health Technol Inform., 122:781-2 (2006)
Evidence for the expression of radiation-induced potentially lethal damage being a p53-dependent process.
Int. J. Radiat. Biol., Aug;76(8):1037-43 (2000)
The effect of functional inactivation of TP53 by HPV-E6 transformation on the induction of chromosome aberrations by gamma rays in human tumor cells.
Radiat. Res., Apr;151(4):385-90 (1999)
Fast neutrons in prostatic adenocarcinomas: worldwide clinical experience.
Recent Results Cancer Res., 150:125-36 (1998)
Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy.
Int. J. Radiat. Oncol. Biol. Phys., Apr;41(1):93-9 (1998)
Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines.
Int. J. Radiat. Oncol. Biol. Phys., Dec;36(5):1099-106 (1996)
Clinical trials of neutron radiotherapy in the United States.
Bull Cancer Radiother., 83 Suppl:78s-86s (1996)
Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells.
Cancer Res., Apr;55(8):1639-42 (1995)
Effect of pentoxifylline on radiation-induced lung and skin toxicity in rats.
Int. J. Radiat. Oncol. Biol. Phys., Jan;31(1):71-7 (1995)
Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial.
Int. J. Radiat. Oncol. Biol. Phys., Jan;28(1):47-54 (1994)
Fast neutron radiation therapy. Results of phase III randomized trials in head and neck, lung, and prostate cancers.
Acta Oncol., 33(3):293-8 (1994)
Fast neutron radiotherapy. The University of Washington experience.
Acta Oncol., 33(3):275-80 (1994)
Femoral vessel depth and the implications for groin node radiation.
Int. J. Radiat. Oncol. Biol. Phys., Nov;27(4):969-74 (1993)
Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer.
Int. J. Radiat. Oncol. Biol. Phys., Aug;26(5):809-16 (1993)
Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial.
Am. J. Clin. Oncol., Apr;16(2):164-7 (1993)
Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.
J. Urol., Oct;146(4):1046-52 (1991)